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segment late loss as the primary study end-point did not significantly differ among the
ZES group and the SES group (0.14±0.38 mm vs. 0.12±0.43 mm, P for
noninferiority=0.03, P for superiority=0.68). The rates of in-segment binary restenosis
was 5.2% in the ZES group and 7.2% in the SES group (P=0.44). The in-stent late loss
(0.26±0.36 mm vs. 0.24±0.42 mm, P=0.78) and in-stent binary restenosis rate (4.0%
vs. 6.0%, P=0.41) were also similar among 2 groups. There were no significant
between-group differences in the rate of adverse events (death, myocardial infarction,
stent thrombosis, target-lesion revascularization, and composite outcomes).
Conclusion: For patients with long native coronary artery disease, as compared with
SES implantation, the Resolute ZES showed similar angiographic late loss and
restenosis rates. Clinical safety and efficacy outcomes were also similar between two
stent groups.
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Background: The PRECOMBAT randomized study showed a non-inferiority of
percutaneous coronary intervention (PCI) with the first-generation sirolimus-eluting
stent (SES) for unprotected left main coronary artery (ULMCA) stenosis compared
with coronary artery bypass graft (CABG) surgery with regard to the incidence of 1-
year major adverse cardiac or cerebrovascular events (MACCE) including death,
myocardial infarction (MI), stroke or ischemia- driven target vessel revascularization
(TVR). However, the safety and efficacy of the second-generation drug-eluting stent
for such lesions are not known well.
Methods: The PRECOMBAT-2 study prospectively enrolled 397 consecutive patients
who received PCI with everolimus-eluting stent (EES) for ULMCA stenosis. From
this registry, the outcomes of 334 (84.1%) patients meeting the randomization criteria
of the PRECOMBAT study were compared with those of patients randomized to SES
(N=327) and CABG (N=272) in the PRECOMBAT study (Figure 1). The primary end
point was the rate of MACCE over 2 years.
Results: Baseline clinical characteristics were well matched among the 3 groups.
Angiographic follow-up was less frequently performed in the EES than in the SES
group due to the less obligatory recommendation (60.8% vs. 76.1%, p<0.001). The
MACCE rate over 2 years did not differ significantly among the 3 groups as shown in
Figure 2 and Table. The 2-year incidences of composite of death, MI or stroke also did
not differ among SES, EES and CABG groups. However, the incidence of ischemia-
driven TVR was lower in the CABG than in the EES or SES groups. Between the EES
and SES groups, the incidences of MACCE and any individual end points were not
different over 2 years.
Conclusion: Stenting with the second-generation EES showed a similar efficacy for
the treatment of ULMCA stenosis, as compared with stenting with the first-eneration
SES or CABG, with regard to the incidence of MACCE over 2 years. Although there
was a tendency of higher repeat revascularization rate after EES than CABG, the two
stent types of EES or SES had comparable long-term safety and efficacy.
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Background: In-stent restenosis continues to be a therapeutic challenge. The present
study aimed to evaluate safety and efficacy of a drug eluting balloon (DEB) releasing
paclitaxel from a butyryl-tri-hexyl citrate (BTHC) excipient in patients with a single
in-stent restenotic lesion (ISR) in coronary arteries.
Methods: Between August 2009 and April 2010, 81 patients were pre-dilated with an
uncoated balloon and treated with the Pantera Lux Paclitaxel Releasing Balloon at 9
European sites. Dual antiplatelet therapy (DAPT) was recommended for 3 months.
Clinical follow up was performed at 1, 6 and 12 months, and angiographic follow up
at 6 months. The primary endpoint was in-stent late lumen loss at 6 months. A
secondary endpoint was major adverse cardiac event (MACE, a composite of cardiac
death, non-fatal MI, clinically driven target lesion revascularization (TLR) and
clinically driven target vessel revascularization (TVR)) rate at 1, 6 and 12 months.
Results: The majority of restenotic lesions from bare metal 43 (53%) and drug eluting
stents 38 (47%) were core lab classified to Mehran class I (71.6% focal) followed by
class II (19.8% diffuse intra-stent). Device success rate was
98.6%. At 6 months, in-stent late lumen loss was 0.07 ± 0.31 mm and MACE rate was
7.8% (1 peri-procedural MI, 1 TVR and 4 TLR). The preliminary MACE rate at 12
months was 11.7% and was driven by 3 additional TLR. 
Conclusion: Twelve-month preliminary MACE results confirmed safety and efficacy
in a mixed population of BMS-ISR and DES-ISR patients for a novel drug eluting
balloon releasing paclitaxel from the excipient BTHC.
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Background: Most powerful predictor of stent thrombosis is endothelial coverage.
Optical Coherence Tomography (OCT) is due to resolution 10um excelent tool to
assess stent healing.
Methods: In our prospective, single centre, randomized study we compared early (14
days) healing in 40 patients treated for stable/unstable angina or non-sustained
myocardial infarction by percutaneous coronary intervention with stent implantation.
40 patient/44stents were randomized into four groups: 10 patients treated by entothelial
progenitor cell capturing stent (GENOUS chromium cobalt stent), 10 pts by Blazer
stent (chromium cobalt stent), 10 pts by SolarFlex (chromium cobalt stent) and 10pts
by NOBORI stent (biolimus eluting coronary stainless steel stent). The standard
technique of stent implantation – baloon/artery ratio 1:1 and 16 bars implantation
pressure – was used. 14 days after successful stent implantation OCT evaluation was
performed. Stent coverage was divided into 3 categories: malapposed, apposed-
uncovered and covered class. The primary endpoint was the percentage of healing
struts, the secondary endpoints were the absolute thickness of neointima and the
percentage of malapposed struts.Total 4413 struts of stents were manually analyzed.
Results: Results are shown in Table No 1, 2 3 and graph No 1.
The most rapid and the most massive healing was observed in GENOUS stents. Also
the absolut thickness of neointima was the highest in GENOUS stent.
Conclusion: The entothelial progenitor cell capturing GENOUS stent provides the
more rapid healing compared with chromium cobalt stents and drug-eluting stent.The
early healing is the powerfull predictor of subacute and late stent thrombosis. Thus, the
high percentage of covered strus probably enable to minimalize the lenght of dual
antiplatelet therapy, especially in patients with encreased bleeding risk. If our results
can be transfered into clinical praxis must be proven in further studies.
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